Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis
Pengxiu Cao, … , Eric R. Fearon, Vibha N. Lama
Pengxiu Cao, … , Eric R. Fearon, Vibha N. Lama
Published February 27, 2017
Citation Information: J Clin Invest. 2017;127(4):1517-1530. https://doi.org/10.1172/JCI88896.
View: Text | PDF
Research Article Cell biology Transplantation

Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis

  • Text
  • PDF
Abstract

Tissue fibrosis is the primary cause of long-term graft failure after organ transplantation. In lung allografts, progressive terminal airway fibrosis leads to an irreversible decline in lung function termed bronchiolitis obliterans syndrome (BOS). Here, we have identified an autocrine pathway linking nuclear factor of activated T cells 2 (NFAT1), autotaxin (ATX), lysophosphatidic acid (LPA), and β-catenin that contributes to progression of fibrosis in lung allografts. Mesenchymal cells (MCs) derived from fibrotic lung allografts (BOS MCs) demonstrated constitutive nuclear β-catenin expression that was dependent on autocrine ATX secretion and LPA signaling. We found that NFAT1 upstream of ATX regulated expression of ATX as well as β-catenin. Silencing NFAT1 in BOS MCs suppressed ATX expression, and sustained overexpression of NFAT1 increased ATX expression and activity in non-fibrotic MCs. LPA signaling induced NFAT1 nuclear translocation, suggesting that autocrine LPA synthesis promotes NFAT1 transcriptional activation and ATX secretion in a positive feedback loop. In an in vivo mouse orthotopic lung transplant model of BOS, antagonism of the LPA receptor (LPA1) or ATX inhibition decreased allograft fibrosis and was associated with lower active β-catenin and dephosphorylated NFAT1 expression. Lung allografts from β-catenin reporter mice demonstrated reduced β-catenin transcriptional activation in the presence of LPA1 antagonist, confirming an in vivo role for LPA signaling in β-catenin activation.

Authors

Pengxiu Cao, Yoshiro Aoki, Linda Badri, Natalie M. Walker, Casey M. Manning, Amir Lagstein, Eric R. Fearon, Vibha N. Lama

×

Figure 5

NFAT1 regulates ATX, β-catenin, and collagen I expression in lung MCs.

Options: View larger image (or click on image) Download as PowerPoint
NFAT1 regulates ATX, β-catenin, and collagen I expression in lung MCs.
(...
(A and B) Expression of NFAT1 protein in whole cell lysate (n = 4/group) and nuclear extract (n = 5–6/group) in BOS and non-BOS MCs measured by immunoblotting with unpaired t test. (C) ATX activity was measured in concentrated cell supernatant from BOS MCs transfected with NFAT1-specific or scrambled siRNA (n = 4/group with 2-way ANOVA). (D) BOS MCs were transfected with siRNAs for NFAT1 or scrambled control, and protein expression of ATX, β-catenin, active β-catenin, and collagen I was analyzed by immunoblotting (n = 7/group). (E) Non-BOS MCs were infected with lentivirus expressing pLentilox-NFAT1-CA-IRES-Puro plasmid or DsRed-expressing vector control, and the indicated protein levels were examined in parallel gels (n = 6/group). NFAT1-CA, constitutively active NFAT1. (F) ATX activity in the cell supernatant from non-BOS MCs infected with lentivirus expressing NFAT1-CA was assayed (n = 3/group with 2-way ANOVA). (G) NFAT1, ATX, AXIN2, and COL1A1 mRNA levels were assayed by real-time PCR in non-BOS MCs infected with lentivirus expressing NFAT1-CA. Mean ± SEM (n = 7–8/group) with paired t test. Experiments were repeated 3 times; *P < 0.05, **P < 0.01, ****P < 0.0001.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts